Pfizer

Aires Pharmaceuticals appoints Edwin L. Parsley as CMO

Wednesday, May 4, 2011 01:05 PM

Aires Pharmaceuticals has hired Ed Parsley, D.O., as chief medical officer.  Parsley will be responsible for all clinical development activities for Aironite, the company's lead product for treatment of pulmonary arterial hypertension (PAH).

More... »

Astellas adds four to team

Tuesday, May 3, 2011 12:33 PM

Astellas Pharma Global Development, a subsidiary of Tokyo-based Astellas Pharma, welcomes four new industry leaders to its team.

More... »

Analysts eye Pfizer break-up

Monday, May 2, 2011 01:22 PM

Analysts have been eyeing the prospect of a Pfizer break-up; they figure Pfizer would be worth $180 billion in pieces, according to Fierce Pharma.

More... »

Regulus Therapeutics appoints Neil W. Gibson as CSO

Monday, April 18, 2011 01:09 PM

Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

More... »

Tafamidis for TTR-FAP shows positive results

Wednesday, April 13, 2011 12:54 PM

Pfizer reported data from an open-label, 12-month extension study (Fx-006) of the pivotal phase II/III (Fx-005) trial. This extension study evaluated the long-term clinical outcomes of tafamidis, an oral, investigational compound being studied as a treatment for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP), a rare and fatal neurodegenerative disease. These data showed that slowing of disease progression was sustained over 30 months.

More... »

Researchers reveal GR and depression link

Wednesday, April 13, 2011 12:38 PM

Scientists in the U.K. using human stem cells say they have discovered how certain antidepressants form new brain cells, according to a Reuters report.  This finding will help researchers develop more effective drugs for treating depression.

More... »

Durect reports Eladur phase II results in back pain

Tuesday, April 12, 2011 12:30 PM

Durect has released results from a phase II clinical trial in chronic low back pain for Eladur (Transdurr-Bupivacaine), Durect's investigational transdermal bupivacaine pain patch. This study was conducted by Durect's collaborator, King Pharmaceuticals, which is now owned by Pfizer. In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between Eladur as compared to placebo was not met.  Complete data analysis is ongoing.

More... »

Pfizer and Medivation reveal results from phase 3 trial of Dimebon

Monday, April 11, 2011 01:03 PM

Pfizer and Medivation reported results from the phase III HORIZON trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).

More... »